{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:35:07Z","timestamp":1792852507730,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004323","name":"Amylin Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jad.2025.04.046","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:43:11Z","timestamp":1744116191000},"page":"116-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults"],"prefix":"10.1016","volume":"382","author":[{"given":"Luis R.","family":"Patino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb M.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Welge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"DelBello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.04.046_bb0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpsychires.2022.02.036","article-title":"Excess mortality in severe mental disorders: a systematic review and meta-regression","volume":"149","author":"Ali","year":"2022","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.jad.2025.04.046_bb0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/schbul\/11.3.380","article-title":"Positive vs. negative schizophrenia: a critical evaluation","volume":"11","author":"Andreasen","year":"1985","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.jad.2025.04.046_bb0015","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.jad.2025.04.046_bb0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11096-015-0219-8","article-title":"The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour","volume":"38","author":"de Boer","year":"2016","journal-title":"Int. J. Clin. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.jad.2025.04.046_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.schres.2012.03.017","article-title":"Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials","volume":"140","author":"Caemmerer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2025.04.046_bb0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fnins.2017.00643","article-title":"Molecular mechanisms of antipsychotic drug-induced diabetes","volume":"11","author":"Chen","year":"2017","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.jad.2025.04.046_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World psychiatry\u202f: official journal of the World Psychiatric Association."},{"issue":"2","key":"10.1016\/j.jad.2025.04.046_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World psychiatry\u202f: official journal of the World Psychiatric Association."},{"issue":"8","key":"10.1016\/j.jad.2025.04.046_bb0045","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1176\/ps.50.8.1036","article-title":"Life expectancy and causes of death in a population treated for serious mental illness","volume":"50","author":"Dembling","year":"1999","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"10.1016\/j.jad.2025.04.046_bb0050","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.jad.2025.04.046_bb0055","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/dom.14050","article-title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","volume":"22","author":"Dube","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jad.2025.04.046_bb0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1741-7015-10-92","article-title":"Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits","volume":"10","author":"Ebdrup","year":"2012","journal-title":"BMC Med."},{"issue":"5","key":"10.1016\/j.jad.2025.04.046_bb0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jad.2025.04.046_bb0070","author":"Guy","year":"1976"},{"issue":"3","key":"10.1016\/j.jad.2025.04.046_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1192\/bjp.bp.117.202606","article-title":"Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014","volume":"211","author":"Hayes","year":"2017","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"issue":"3","key":"10.1016\/j.jad.2025.04.046_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/acps.12045","article-title":"Avoidable mortality in people with schizophrenia or bipolar disorder in England","volume":"127","author":"Hoang","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.jad.2025.04.046_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes. Rev."},{"issue":"2","key":"10.1016\/j.jad.2025.04.046_bb0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ishoy","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jad.2025.04.046_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eurpsy.2017.02.487","article-title":"Contributions of specific causes of death to lost life expectancy in severe mental illness","volume":"43","author":"Jayatilleke","year":"2017","journal-title":"European psychiatry: the journal of the Association of European Psychiatrists"},{"issue":"3","key":"10.1016\/j.jad.2025.04.046_bb0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocr. Res."},{"issue":"7","key":"10.1016\/j.jad.2025.04.046_bb0105","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.jad.2025.04.046_bb0110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/oby.2007.133","article-title":"Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder","volume":"16","author":"Kolotkin","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"10.1016\/j.jad.2025.04.046_bb0115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of Liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia Spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.04.046_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024597","article-title":"Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder","volume":"6","author":"Laursen","year":"2011","journal-title":"PloS One"},{"issue":"9896","key":"10.1016\/j.jad.2025.04.046_bb0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jad.2025.04.046_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152223","article-title":"Excess mortality in patients with severe mental disorders in 1996-2010 in Finland","volume":"11","author":"Lumme","year":"2016","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jad.2025.04.046_bb0135","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/archgenpsychiatry.2012.934","article-title":"Neural correlates of weight gain with olanzapine","volume":"69","author":"Mathews","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.04.046_bb0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.jad.2025.04.046_bb0145","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis","volume":"40","author":"Mizuno","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2025.04.046_bb0150","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"The British journal of psychiatry\u202f: the journal of mental science"},{"key":"10.1016\/j.jad.2025.04.046_bb0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.jad.2025.04.046_bb0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"12","key":"10.1016\/j.jad.2025.04.046_bb0165","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.04.046_bb0170","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamapsychiatry.2014.2133","article-title":"Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program","volume":"72","author":"Osborn","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.04.046_bb0175","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/eurpub\/ckv245","article-title":"Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010","volume":"26","author":"Osby","year":"2016","journal-title":"Eur. J. Public Health"},{"issue":"8","key":"10.1016\/j.jad.2025.04.046_bb0180","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/dom.14732","article-title":"Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: a randomized controlled trial","volume":"24","author":"van Ruiten","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.jad.2025.04.046_bb0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.04.046_bb0190","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.jad.2025.04.046_bb0195","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000502293","article-title":"Lifestyle interventions for weight Management in People with serious mental illness: a systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects","volume":"88","author":"Speyer","year":"2019","journal-title":"Psychother. Psychosom."},{"issue":"6","key":"10.1016\/j.jad.2025.04.046_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.53","article-title":"Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment","volume":"2","author":"Stip","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.04.046_bb0205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.04.046_bb0210","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jad.2025.04.046_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2025.04.046_bb0220","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"The British journal of psychiatry\u202f: the journal of mental science."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272500607X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272500607X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:42:09Z","timestamp":1778244129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272500607X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"alternative-id":["S016503272500607X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.046","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}